Bristol-Myers Squibb   2Q Revenues: $4.4 billion (-18%) 2Q Earnings: $808 million (-38%) YTD Revenues: $9.7 billion (-7%) YTD Earnings: $2.3 billion (-14%) Comments: U.S. sales were down 27% to $2.6 billion in the quarter due to patent expirations for Avapro/Avalide (-40%) and Plavix (-33%). Abilify sales were $711 million (+1%). Reyataz sales were $406 million (+3%). Sustiva Franchise sales were $388 million (+5%). Onglyza/Kombiglyze sales were up 54% to $174 million, Baraclude sales were u...